Institute of Hematology & Blood Diseases Hospital, China
Phase
Observational
Started
2025-09-25
Last updated
2025-08-26
Condition(s) studied
Infections, Cytomegalovirus
Investigational drug(s) / intervention(s)
maribavir
maribavir: Maribavir tablets are administered orally at a dose of 0.4 g per administration (2 tablets of 0.2 g each), twice daily. The recommended duration of treatment is 8 weeks; however, the specific treatment duration should be individualized based on the clinical characteristics of each patient.
Study summary
The main aim of this study is to check the effectiveness and safety of maribavir for the treatment of CMV infection after HSCT in Chinese patients in real-world settings.
The participants will be treated with maribavir for up to 8 weeks.
Eligibility
Sex
ALL
Min age
12 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
* Hematopoietic Stem Cell Transplant Recipients
1. Adult patients with an expected survival of ≥4 weeks.
2. Confirmed CMV infection, including CMV viremia and CMV disease.
3. Fully understand the content of the trial, voluntarily participate and complete the trial, and voluntarily sign the informed consent form.
Exclusion Criteria:
* Participants who meet any of the following criteria are not eligible for this study:
1. Patients currently participating in other CMV-related clinical studies, such as those receiving anti-CMV drug treatment or involved in CMV vaccine clinical studies.
2. At screening, liver function tests show: AST \> 5×ULN, or ALT \> 5×ULN, or total bilirubin ≥ 3.0×ULN.
3. Patients with psychiatric disorders or severe psychological conditions that may affect the ability to provide informed consent or participate in follow-up consultations.
4. Participants deemed unsuitable for inclusion by the investigator.
Primary outcome measure(s)
CMV viremia clearance rate — At Week 4 The proportion of patients who had confirmed clearance of CMV viremia in plasma (defined as two consecutive CMV-DNA tests below the preemptive treatment threshold after treatment) after 4 weeks of treatment.
CMV disease remission rate — At Week 4 The proportion of patients who achieved remission of CMV disease after 4 weeks of treatment.
Trial sites (1)
Facility
City
Region
Status
Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences
Tianjin
Tianjin Municipality
More Institute of Hematology & Blood Diseases Hospital, China trials in China
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.